• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

QM-FISH 技术在单细胞水平检测多发性骨髓瘤关键细胞遗传学异常的克隆进化。

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

The Second Hospital of Shanxi Medical University, Taiyuan, China.

出版信息

Blood Adv. 2022 Jan 25;6(2):441-451. doi: 10.1182/bloodadvances.2021004992.

DOI:10.1182/bloodadvances.2021004992
PMID:34653241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8791565/
Abstract

Single-cell analysis is of significant importance in delineating the exact phylogeny of the subclonal population and in discovering subtle diversification. So far, studies of intratumor heterogeneity and clonal evolution in multiple myeloma (MM) were largely focused on the bulk tumor population level. We performed quantitative multigene fluorescence in situ hybridization (QM-FISH) in 129 longitudinal samples of 57 MM patients. All the patients had newly diagnosed and relapsed paired samples. An expanded cohort of 188 MM patients underwent conventional FISH (cFISH) to validate the cytogenetic evolution in bulk tumor level. Forty-three of 57 patients (75.4%) harbored 3 or 4 cytogenetic clones at diagnosis. We delineated the phylogeny of the subclonal tumor population and derived the evolutionary architecture in each patient. Patients with clonal stabilization had a significantly improved overall survival (OS) than those with other evolutionary patterns (median OS, 71.2 months vs 39.7 months vs 35.2 months vs 25.5 months, for stable, differential, branching, and linear patterns, respectively; P = .001). A high degree of consistency and complementarity across QM-FISH and cFISH was observed in the evaluation of cytogenetic evolution patterns in MM. Survival after relapse was greater influenced by the presence of high-risk aberrations at relapse (hazard ratio = 2.07) rather than present at diagnosis (hazard ratio = 1.55). This study shows that QM-FISH is a valuable tool to elucidate the clonal architecture at the single-cell level. Clonal evolution pattern is of prognostic significance, highlighting the need for repeated cytogenetic evaluation in relapsed MM.

摘要

单细胞分析对于描绘亚克隆群体的准确系统发育以及发现微妙的多样化具有重要意义。到目前为止,多发性骨髓瘤(MM)中的肿瘤内异质性和克隆进化研究主要集中在肿瘤整体水平上。我们对 57 名 MM 患者的 129 个纵向样本进行了定量多基因荧光原位杂交(QM-FISH)。所有患者均为初诊和复发配对样本。188 名 MM 患者的扩展队列接受了常规 FISH(cFISH)以验证肿瘤整体水平的细胞遗传学演变。57 名患者中有 43 名(75.4%)在诊断时存在 3 或 4 个细胞遗传学克隆。我们描绘了亚克隆肿瘤群体的系统发育,并得出了每个患者的进化结构。具有克隆稳定的患者的总体生存率(OS)明显优于具有其他进化模式的患者(中位 OS,稳定型为 71.2 个月,差异型为 39.7 个月,分支型为 35.2 个月,线性型为 25.5 个月;分别为 P =.001)。在评估 MM 中的细胞遗传学演变模式时,QM-FISH 和 cFISH 之间表现出高度的一致性和互补性。复发后的生存受复发时高风险异常的存在(危险比=2.07)而不是初诊时的存在(危险比=1.55)的影响更大。这项研究表明,QM-FISH 是阐明单细胞水平克隆结构的有价值的工具。克隆进化模式具有预后意义,强调了在复发 MM 中需要重复进行细胞遗传学评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/6ac4144e3b66/advancesADV2021004992f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/b9fe05ede18d/advancesADV2021004992absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/609464af16a9/advancesADV2021004992f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/2167f93b707c/advancesADV2021004992f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/e4b57b3e373d/advancesADV2021004992f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/32cc157b9bcb/advancesADV2021004992f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/cf0d16dc566d/advancesADV2021004992f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/6ac4144e3b66/advancesADV2021004992f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/b9fe05ede18d/advancesADV2021004992absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/609464af16a9/advancesADV2021004992f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/2167f93b707c/advancesADV2021004992f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/e4b57b3e373d/advancesADV2021004992f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/32cc157b9bcb/advancesADV2021004992f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/cf0d16dc566d/advancesADV2021004992f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a464/8791565/6ac4144e3b66/advancesADV2021004992f6.jpg

相似文献

1
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.QM-FISH 技术在单细胞水平检测多发性骨髓瘤关键细胞遗传学异常的克隆进化。
Blood Adv. 2022 Jan 25;6(2):441-451. doi: 10.1182/bloodadvances.2021004992.
2
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.克隆大小对多发性骨髓瘤中荧光原位杂交染色体异常预后价值的影响。
Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.
3
Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.纵向荧光杂交显示自体移植后复发骨髓瘤的细胞遗传学演变。
Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.
4
Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.对处于诊断和进展/复发两个不同阶段的多发性骨髓瘤患者8号染色体畸变的分子细胞遗传学分析。
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):358-65. doi: 10.1016/j.clml.2016.02.038. Epub 2016 Feb 27.
5
Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?通过多色间期荧光原位杂交(FISH)定义的脑膜瘤瘤内克隆进化模式:组织病理学上的良性病变与非典型/间变性病变之间是否存在关联?
J Mol Diagn. 2004 Nov;6(4):316-25. doi: 10.1016/S1525-1578(10)60527-2.
6
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.采用间期荧光原位杂交技术研究多发性骨髓瘤患者的分子细胞遗传学畸变。
Exp Oncol. 2007 Jun;29(2):116-20.
7
Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.意义未明的单克隆丙种球蛋白病与多发性骨髓瘤及浆细胞白血病中非整倍体模式的荧光原位杂交分析
Cancer. 2003 Feb 1;97(3):601-9. doi: 10.1002/cncr.11100.
8
The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.细胞遗传学演变和 17p 缺失获得对多发性骨髓瘤患者预后的影响。
Pol Arch Intern Med. 2020 Jun 25;130(6):483-491. doi: 10.20452/pamw.15316. Epub 2020 Apr 27.
9
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.17p 号染色体缺失微小克隆为多发性骨髓瘤复发提供了一个蓄水池。
Haematologica. 2024 Feb 1;109(2):591-603. doi: 10.3324/haematol.2023.283533.
10
[Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].CD138免疫磁珠分选骨髓瘤细胞联合荧光原位杂交技术在检测多发性骨髓瘤细胞遗传学异常中的应用
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Jun;25(3):807-812. doi: 10.7534/j.issn.1009-2137.2017.03.031.

引用本文的文献

1
Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.在多种涉及免疫球蛋白重链(IgH)细胞遗传学异常的高危分层中,应对多发性骨髓瘤中IgH细胞遗传学异常的预后复杂性
Cancer Med. 2025 Sep;14(17):e71152. doi: 10.1002/cam4.71152.
2
A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.基于 1q21 增益/扩增的多发性骨髓瘤生存预后预测风险评分模型:中国西南部一家三级医院的经验。
Cancer Med. 2024 Sep;13(17):e70193. doi: 10.1002/cam4.70193.
3

本文引用的文献

1
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.1q21 额外拷贝在多发性骨髓瘤中的预后价值取决于主要的遗传事件。
Am J Hematol. 2020 Dec;95(12):1562-1571. doi: 10.1002/ajh.25994. Epub 2020 Sep 19.
2
The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.1q21 增益/扩增在多发性骨髓瘤中矛盾的预后作用:事物都具有两面性。
Leuk Lymphoma. 2020 Oct;61(10):2351-2364. doi: 10.1080/10428194.2020.1772473. Epub 2020 Jun 10.
3
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.
通过单细胞测序鉴定多发性骨髓瘤微小残留病灶克隆中的治疗诱导的克隆进化和耐药途径。
Clin Cancer Res. 2024 Sep 3;30(17):3919-3936. doi: 10.1158/1078-0432.CCR-24-0545.
4
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.LILRB4 是多发性骨髓瘤中通过双重靶向肿瘤细胞和髓源性抑制细胞的免疫治疗的一个有前途的靶点。
Haematologica. 2024 Nov 1;109(11):3650-3669. doi: 10.3324/haematol.2024.285099.
5
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.荧光原位杂交揭示多发性骨髓瘤中增益/扩增(1q)小克隆的进化生物学。
Leukemia. 2024 Jun;38(6):1299-1306. doi: 10.1038/s41375-024-02237-3. Epub 2024 Apr 12.
6
Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation.多组学研究对多发性骨髓瘤起始、演变和进展的新见解
Cancers (Basel). 2024 Jan 24;16(3):498. doi: 10.3390/cancers16030498.
7
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities.尽管存在并发染色体异常,但MAF易位仍然是一个强有力的预后因素。
Haematologica. 2024 May 1;109(5):1619-1623. doi: 10.3324/haematol.2023.284666.
8
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).免疫表型特征定义细胞遗传学稳定性,并揭示新诊断多发性骨髓瘤(NDMM)患者的不同预后。
Ann Hematol. 2024 Apr;103(4):1305-1315. doi: 10.1007/s00277-023-05573-z. Epub 2023 Dec 5.
9
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.17p 号染色体缺失微小克隆为多发性骨髓瘤复发提供了一个蓄水池。
Haematologica. 2024 Feb 1;109(2):591-603. doi: 10.3324/haematol.2023.283533.
10
Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy.多发性骨髓瘤的治疗策略和高通量筛选在精准癌症治疗中的作用。
Adv Exp Med Biol. 2023;1436:167-185. doi: 10.1007/5584_2023_775.
1q21 增益而非 t(4;14) 预示着硼替佐米治疗多发性骨髓瘤的不良预后。
Leuk Lymphoma. 2020 May;61(5):1201-1210. doi: 10.1080/10428194.2019.1700503. Epub 2019 Dec 16.
4
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.监测微小残留血浆细胞的细胞遗传学结构可表明多发性骨髓瘤的治疗诱导的克隆选择。
Leukemia. 2020 Feb;34(2):578-588. doi: 10.1038/s41375-019-0590-x. Epub 2019 Oct 7.
5
1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.1q21 增益合并高危因素是中国新诊断多发性骨髓瘤的异质性预后因素:一项多中心研究。
Oncologist. 2019 Nov;24(11):e1132-e1140. doi: 10.1634/theoncologist.2019-0132. Epub 2019 Aug 27.
6
Genomic landscape and chronological reconstruction of driver events in multiple myeloma.多发性骨髓瘤中驱动事件的基因组全景和时间重建。
Nat Commun. 2019 Aug 23;10(1):3835. doi: 10.1038/s41467-019-11680-1.
7
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.多发性骨髓瘤患者细胞遗传学预后指数的建立与验证:对生存的预测作用。
J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.
8
Resolving genetic heterogeneity in cancer.解析癌症中的遗传异质性。
Nat Rev Genet. 2019 Jul;20(7):404-416. doi: 10.1038/s41576-019-0114-6.
9
Deciphering the chronology of copy number alterations in Multiple Myeloma.解读多发性骨髓瘤中拷贝数改变的时间顺序。
Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.
10
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.骨髓瘤中的克隆进化:维持来那度胺和缓解深度对经统一治疗的初诊新发患者复发疾病的遗传学和亚克隆结构的影响。
Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.